SIRPA and glioblastoma: A landmark study by Gholamin, Mitra and colleagues performed a comprehensive in vivo analysis of the effect of Hu5F9-G4 against different paediatric brain cancers, including glioblastoma.420 These data were validated in vivo using the SU-GBM044 patient-derived cell line model of adult glioblastoma,425 proving that inhibiting the CD47-SIRPα interaction can improve the survival of mice with glioblastoma.